ELOX on Nasdaq

Eloxx Pharmaceuticals, Inc.

American biological products company based in Bridgewater, active since 1999. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Fate Therapeutics, DBV Technologies or Evaxion A/S, or pick any stock.

  • TickerELOX on Nasdaq2
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersBridgewater, United States2
  • Incorporated inDE3
  • Business addressP.O. Box 274, Arlington, Ma 024763
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300UB28QGWJMFFA112
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Corporation Service Company, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 31048092

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (“NMs”) to enable the production of full-length proteins. Targeting ribosome subunits provides a therapeutic approach to addressing a number of genetic diseases. According to the Human Gene Mutation Database, NMs account for approximately 10% to 12% of patients with a given genetic disease. There are over 7,000 inherited genetic diseases that collectively affect 350 million people worldwide. Our immediate focus is to advance the clinical development of our lead product candidate, exaluren, for the treatment of rare kidney diseases and, through our collaboration with Almirall, S.A. (“Almirall”), ZKN-013 for the treatment of rare skin diseases.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20255

Financial statements

Revenue5$0 in 2025
0$2.0M$4.0M$6.0M$8.0M2023: $0$020232024: $6.4M$6.4M20242025: $0$02025
Operating income675-$6.4M in 2025−87% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$50.6M-$50.6M20192020: -$33.5M-$33.5M2020−34%2021: -$66.0M-$66.0M2021+97%2022: -$34.4M-$34.4M2022−48%2023: -$17.3M-$17.3M2023−50%2024: -$2.5M-$2.5M2024−86%2025: -$6.4M-$6.4M2025+161%
Net income675-$6.0M in 2025−88% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$50.9M-$50.9M20192020: -$34.6M-$34.6M2020−32%2021: -$66.7M-$66.7M2021+93%2022: -$36.1M-$36.1M2022−46%2023: -$17.1M-$17.1M2023−53%2024: -$3.1M-$3.1M2024−82%2025: -$6.0M-$6.0M2025+91%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
License and service revenue:$0$6.4M$0
Research and development$3.1M$3.6M$8.6M
General and administrative$3.4M$5.2M$8.7M
Total operating expenses$6.4M$8.8M$17.3M
Loss from operations-$6.4M-$2.5M-$17.3M
Other (income) expense, net-$443.0K$675.0K-$234.0K
Net loss-$6.0M-$3.1M-$17.1M
Net loss per share, basic-$0.49-$0.84-$6.63
Net loss per share, diluted-$0.49-$0.84-$6.63
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic12.3M shares3.8M shares2.6M shares
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, diluted12.3M shares3.8M shares2.6M shares

Compare Eloxx Pharmaceuticals, Inc. with another company

Leadership

Who has led Eloxx Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bruce C. Galton2006–2008
  2. Hulst Jack Van2009–2010
  3. Leslie J. Browne2010–2013
  4. Ron Martell2014
  5. Silvia Noiman2017–2018
  6. Gregory C. Williams2020–2021
  7. Sumit Aggarwal2021–now

President

  1. Bruce C. Galton2006–2008
  2. Hulst Jack Van2009–2010
  3. Leslie J. Browne2010–2014
  4. Sumit Aggarwal2021–now

Chief financial officer

  1. Joel Brooks2006–2014
  2. Daniel E. Geffken2021

Chief operating officer

  1. Gregory C. Williams2018–2020
  2. Neil S. Belloff2020–2021
2010201520202025
Board members and other officers (37)

Former names

  • Sevion Therapeutics, Inc.Oct 3, 2014 to Dec 22, 20173
  • SENESCO TECHNOLOGIES INCNov 19, 1999 to Sep 29, 20143
  • NAVA LEISURE USA INCOct 7, 1997 to May 24, 19993

Timeline

  1. Apr 2, 2021New chief executive Sumit Aggarwal becomes CEO12
  2. Feb 26, 2020New chief executive Gregory C. Williams becomes CEO13
  3. Dec 29, 2017New chief executive Silvia Noiman becomes CEO14
  4. Jun 26, 2014New chief executive Ron Martell becomes CEO15
  5. May 27, 2010New chief executive Leslie J. Browne becomes CEO16
  6. Nov 23, 2009New chief executive Hulst Jack Van becomes CEO17
  7. Apr 24, 2006New chief executive Bruce C. Galton becomes CEO18
  8. Sep 30, 1999Founded Eloxx Pharmaceuticals, Inc. is founded2

Filings

155 filings to the SEC since October 2021: 3 annual reports, 9 quarterly reports, 44 major events, 48 insider forms, 16 large holders, 35 other. The latest 20:

  1. Sep 18, 2026EFFECT EDGAR
  2. Sep 11, 2026S-1 EDGAR
  3. Aug 14, 2026SCHEDULE 13G EDGAR
  4. Aug 14, 2026SCHEDULE 13G EDGAR
  5. Aug 11, 20268-K EDGAR
  6. Aug 11, 202610-Q EDGAR
  7. Jul 27, 2026SCHEDULE 13G EDGAR
  8. Jun 17, 2026SCHEDULE 13G EDGAR
  9. Jun 17, 2026SCHEDULE 13G EDGAR
  10. Jun 17, 20264 EDGAR
  11. Jun 17, 20263 EDGAR
  12. Jun 16, 2026SCHEDULE 13G EDGAR
  13. Jun 16, 2026SCHEDULE 13G EDGAR
  14. Jun 15, 2026SCHEDULE 13G EDGAR
  15. Jun 10, 20264 EDGAR
  16. Jun 10, 20264 EDGAR
  17. Jun 10, 20264 EDGAR
  18. Jun 10, 20264 EDGAR
  19. Jun 10, 20264 EDGAR
  20. Jun 9, 2026424B4 EDGAR

The 155 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 29, 2021Geffken Daniel E.INTERIM CFOBuy50,000$0.72$36.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC800,000$11.1M0.3%New
EcoR1 Capital, LLC400,000$5.6M0.3%New
Aberdeen Group plc400,000$5.6M0.0%New
Samsara Biocapital, LLC400,000$5.6M0.5%New
Siren, L.L.C.400,000$5.6M0.1%New
Stonepine Capital Management, LLC397,160$5.5M4.2%New
Vanguard Capital Management LLC78,680$1.1M0.0%New
Vanguard Fiduciary Trust Co10,602$147.2K0.0%New
Seven Grand Managers, LLC10,000$138.8K0.0%New
Morgan Stanley1,544$21.4K0.0%New
Vanguard Global Advisers, LLC718$10.0K0.0%New
UBS Group AG637$8.8K0.0%New
Wells Fargo & Company/mn126$1.7K0.0%New
Pioneer Family Office, LLC96$1.3K0.0%New
Royal Bank Of Canada98$1.0K0.0%New
Altshuler Shaham Ltd25$3470.0%New
Barclays PLC12$1670.0%New
Towne Trust Company, N.A5$690.0%New
Citigroup Inc4$560.0%New
Activest Wealth Management4$560.0%New
SBI Securities Co., Ltd.2$280.0%New
Point Nemo Capital, LLC1$140.0%New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64